My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares ESG Aware 60/40 Balanced Allocation ETF (NY:EAOR)

34.91 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares ESG Aware 60/40 Balanced Allocation ETF

Acadia Healthcare Stock Surges Pre-Market After Activist Hedge Fund Reportedly Seeks Board Revamp
Via Stocktwits
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
Via Stocktwits
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
Via Stocktwits
Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study
Via Stocktwits
Oklo Stock Continues To Be The Talk Of The Town After Gaining 87% In A Month – Here’s How Retail Investors Responded
Via Stocktwits
Cracker Barrel In Spotlight After Slew Of Price Target Cuts: Citi Says Q1 Began In A ‘Deep Traffic Hole’ Post Logo Change
Via Stocktwits
Duolingo Stock Dips After Citigroup Lowers Price Target – Here’s What The Analyst Said About Duocon Event
Citigroup maintained a ‘Buy’ rating and noted that Duolingo's product announcements this year had a lower profile relative to the past. 
Via Stocktwits
Topics Artificial Intelligence
RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite
Via Stocktwits
Topics Government
This Aerospace Stock Witnessed A 700% Explosion In Retail Chatter On Stocktwits – More Details Inside
Via Stocktwits
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
Via Stocktwits
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR. 
Via Stocktwits
Topics Death
Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study
After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 
Via Stocktwits
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 
Via Stocktwits
Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why
Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal. 
Via Stocktwits
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided
Via Stocktwits
Inspire Medical Systems Stock Slumps On Downgrades, Price Target Cuts: Retail Believes Stock Is Way Oversold
Via Stocktwits
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier
Via Stocktwits
CVS Health CFO Says Company Maintaining Prudent View On Medical Cost Trends Through Remainder Of Year
The firm now expects full-year adjusted earnings per share of $6.30 to $6.40, up from its previous guidance of $6.00 to $6.20. 
Via Stocktwits
Topics Artificial Intelligence Earnings Workforce
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys
JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. 
Via Stocktwits
Topics Death
Moderna’s Covid Vaccine Gets Full FDA Approval For Use In Children 6 Months And Older
The vaccine was previously available for pediatric populations under Emergency Use Authorization only. 
Via Stocktwits
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results
Organon said that the mid-stage study evaluating its OG-6219 in endometriosis-related pain did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to... 
Via Stocktwits
Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial
The data is key to receiving approvals for both the individual vaccine candidate and the company’s seasonal flu-COVID combination vaccine candidate. 
Via Stocktwits
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.